Elevance Health
ELV stock analysis · Health Care · Managed Health Care
As of · fund-implied per-share value
Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.
View SEC fund filing ↗Price × SEC outstanding shares. Shares measured 2026-06-30. Approximate; share and price dates can differ.
View share-count filing ↗DCF value
Equity cash-flow scenario · SEC outstanding shares at 2026-06-30 · -42.5% versus input cap
How this is calculated ↗Reverse DCF
Annual basis · read assumptions below
How this is calculated ↗Relative valuation
52 sector peers · median 26.0×
How this is calculated ↗Historical multiples
7 annual observations · snapshot P/E 14.8× · -9.6% versus history
How this is calculated ↗Free cash flow yield
Annual basis · read assumptions below
How this is calculated ↗ROIC / quality
Normalized tax · financing-capital proxy
How this is calculated ↗Value composite
Annual basis · read assumptions below
How this is calculated ↗12–1 price momentum
Split and corporate-action verification is incomplete for these fund observations. Verified adjusted endpoints are required for 12–1 momentum.
How this is calculated ↗Asset growth
Annual basis · read assumptions below
How this is calculated ↗Net payout yield
Annual basis · read assumptions below
How this is calculated ↗Accrual quality
Annual basis · read assumptions below
How this is calculated ↗Fundamental momentum
Annual basis · read assumptions below
How this is calculated ↗Follow the cash
ANNUAL · USDOperating cash flow and reinvestment over time
Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.
Make the assumptions yours
How sensitive is the valuation?
| Return / Growth | 3.0% | 5.0% | 7.0% |
|---|---|---|---|
| 8.0% | $278.85 | $304.26 | $331.57 |
| 10.0% | $204.34 | $222.32 | $241.63 |
| 12.0% | $161.21 | $174.93 | $189.64 |
Annual financial history
Open SEC filings ↗| Fiscal year-end | Revenue | Net income | Operating cash flow | Capital expenditure | Assets |
|---|---|---|---|---|---|
| 2025-12-31 | 199.1B | 5.7B | 4.3B | 1.1B | 121.5B |
| 2024-12-31 | 177B | 6B | 5.8B | 1.3B | 116.9B |
| 2023-12-31 | 171.3B | 6B | 8.1B | 1.3B | 108.9B |
| 2022-12-31 | 156.6B | 5.9B | 8.4B | 1.2B | 102.8B |
| 2021-12-31 | 138.6B | 6.1B | 8.4B | 1.1B | 97.5B |
| 2020-12-31 | 121.9B | 4.6B | 10.7B | 1B | 86.6B |
| 2019-12-31 | 104.2B | 4.8B | 6.1B | 1.1B | 77.5B |
| 2018-12-31 | 92.1B | 3.8B | 3.8B | 1.2B | 71.6B |
USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.
Trace the inputs
MODEL ANNUAL PERIOD| Input | Value | SEC tag / source | Filed |
|---|---|---|---|
| revenue | 199.1B | Revenues | 2026-02-06 |
| netIncome | 5.7B | ProfitLoss Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-06 |
| Parent/common earnings proxy | 5.7B | NetIncomeLoss | 2026-02-06 |
| cfo | 4.3B | NetCashProvidedByUsedInOperatingActivities | 2026-02-06 |
| capex | 1.1B | PaymentsToAcquirePropertyPlantAndEquipment | 2026-02-06 |
| operatingIncome | 7.2B | OperatingIncomeLoss | 2026-02-06 |
| assets | 121.5B | Assets | 2026-02-06 |
| equity | 44B | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-06 |
| Parent book equity proxy | 43.9B | StockholdersEquity | 2026-02-06 |
| debt | 31.9B | LongTermDebt | 2026-02-06 |
| shortDebt | 150M | ShortTermBorrowings | 2026-02-06 |
| cash | 9.5B | CashAndCashEquivalentsAtCarryingValue | 2026-02-06 |
| shares | 224.6M | WeightedAverageNumberOfDilutedSharesOutstanding | 2026-02-06 |
| dividends | 1.5B | PaymentsOfDividends | 2026-02-06 |
| buybacks | 2.6B | PaymentsForRepurchaseOfCommonStock | 2026-02-06 |
| issuance | 79M | Reviewed manual correction Bounded FY2025-12-31 consolidated financing-statement extraction. Proceeds from issuance of common stock under employee stock plans: 79000000 USD [us-gaap:ProceedsFromStockPlans]. All 11 financing lines reconcile exactly to reported financing cash flow -1738000000 USD. Cash inflows from common shares, employee plans and option exercises are summed once as displayed on the statement; noncash compensation, withholding payments, preferred and noncontrolling interests are excluded. This review applies only to this issuer and fiscal period. Source limitation: the statement also aggregates other financing cash flows (net 22000000 USD). Their common-equity portion is not separately disclosed here. Issuance is the sum of separately reported common cash-issuance lines, not an independently verified gross total; additional equity flows may be inside those aggregates. | 2026-02-06 |